The mission of NNECOS is to promote the highest quality care for patients with cancer and blood disorders in our region through professional networking, education, and scientific research, as well as patient advocacy and public policy.

NAHPAC Openings

Learn more on our NAHPAC page.


Congratulations, Dr. Meehan, on your Excellence in Teaching Award! NNECOS Board Member, Dr. Ken Meehan, center, pictured with Fellow Board Liaison Dr. Odeth Barrett-Campbell and Fellow Dr. Lukas Emery.

Patient Assistance Presentation Series

Register for the series today and be sure to sign up for NNECOS sponsored lunch!

Lunchtime Webinar Series

Lunchtime Best Oncology Practice Series

Sign up for the monthly series today. Continuing Nursing Education available for some sessions! 


OCN Review Course

Get Involved with a NNECOS Task Force

New Job Posted - NNECOS Classifieds

  • Northern Light Health - Physician Medical Director -Oncology Service Line
  • UVM Cancer Center / Larner College of Medicine 
    • Academic clinician with experience in lung cancer, melanoma and immunotherapy - Assistant or Associate Professor in the Clinical Scholars Pathway
    • Physician-scientist/academic clinician with experience in breast cancer - Associate Professor or Full Professor in the Clinical Scholar Pathway
    • Classical hematologist - Assistant Professor, Associate Professor, or Professor in the Clinical Scholar Pathway
  • DHMC Norris Cotton Cancer Center - oncologist positions at Dartmouth-Hitchcock Keene / Cheshire Medical Center, Dartmouth-Hitchcock Manchester & Concord, and Southwestern Vermont Regional Cancer Center
  •  Northern Light Health Eastern Maine Medical Center - Clinical Research Nurse
  • Northern Light Health Eastern Maine Medical Center - Board-certified/board eligible hematologist/oncologist
  • New England Cancer Specialists - multiple positions


Please read this special message to our community.

Latest FDA Approvals And Drug-Related Updates

Latest FDA Approvals

  • June 22nd - FDA grants accelerated approval to dabrafenib in combination with trametinib for unresectable or metastatic solid tumors with BRAF V600E mutation
  • May 27th - FDA approves tisagenlecleucel for relapsed or refractory follicular lymphoma
  • May 27th - FDA approves Opdivo in combination with chemotherapy and Opdivo in combination with Yervoy for first-line esophageal squamous cell carcinoma indications
  • May 25th - FDA approves ivosidenib in combination with azacitidine for newly diagnosed acute myeloid leukemia
  • May 20th - FDA approves azacitidine for newly diagnosed juvenile myelomonocytic leukemia
Package/Label Updates
Code Updates

Other Updates

State Advocacy

ASCO Twitter Feeds





Thank You Corporate Members!

Group Practice Members

Because your entire team benefits
from being a part of NNECOS!


ASCO Survey on COVID in Oncology Registry

The aim is to help the cancer community learn more about the patterns of symptoms & severity of COVID among patients with cancer, as well as the impact on delivery of cancer care & patient outcomes. Periodic reports will deliver real-time information to the oncology community.

ASCO COVID Resource Page

COVID Info & Resources including a Fact Sheet on EUA of BAmlanivimab


Looking Back!

Enjoy this wonderful interview with 3 of NNECOS' founding members!

Special thanks to our 2022 Diamond & Platinum Corporate Members!


Platinum Members



View the complete list of supporters.

Northern New England Clinical Oncology Society
P.O. Box 643
Sandown, NH 03873-0643
Telephone (603) 887-1948

This website brought to you by:

Powered by Wild Apricot Membership Software